The American Food and Drug Administration made the announcement on August 19th that fast-track approval has been granted to a new drug by the name of Adcetris, which is to be used to treat both systemic anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma. Researchers responsible for the study has also noted hugely optimistic results with chronic lymphocytic leukemia (CLL).
Such has sparked a fresh and concentrated wave of interest in the research toward workable cancer treatments across the board and increased government assistance. There are currently no less than 14 million cancer survivors within the US and researchers coast to coast are once again campaigning that their work be recognized as of paramount importance.
Furthermore, it has been called into question as to exactly how fair the current system in the US is, with patients of all forms of cancer being denied access to certain treatments by one arm of the government (CMS), especially give the fact that taxpayer money contributed toward the treatment’s development.
There are a number of factors contributing toward patients not receiving 100% of the care and treatment they should, sparking another online petition to be circulated with regard to the government’s handling of its Medicare and Medical reimbursement of RIT.
